Drug Trial News

RSS

QRxPharma receives new U.S. Patent for MoxDuo IR in treatment of acute pain

QRxPharma Limited announced today that the United States Patent and Trademark Office issued the Company a new patent, U.S. Patent #7,923,453, which expires in 2029. This patent covers a proprietary dosing algorithm for converting patients from intravenous opioid administration to orally administered MoxDuo IR, thereby more effectively and safely managing acute pain following surgery.

15 Apr 2011

Perampanel drug can effectively treat seizures in patients with epilepsy

A new drug called perampanel appears to significantly reduce seizures in people with hard-to-control epilepsy, according to results of the first clinical trial to test the higher 12 mg dose of the drug.

15 Apr 2011

Yissum announces successful Docetaxel pre-clinical data in cancer

Yissum Research Development Company Ltd., the technology transfer company of the Hebrew University of Jerusalem, announced today successful pre-clinical data of oral delivery of Docetaxel, an anti-cancer drug, utilizing a novel nanotechnology platform.

12 Apr 2011

Teva presents new CNS products study data in RRMS, Parkinson's at AAN meeting

Teva Pharmaceutical Industries Ltd. today announced that several new studies further support the efficacy and safety of the company's innovative central nervous system products.

12 Apr 2011

Sirolimus may help treat lymphangioleiomyomatosis in women

An Oregon Health & Science University researcher has co-authored an international study that revealed a drug approved to prevent rejection in organ transplant patients helped treat a rare lung disease in women.

12 Apr 2011

Positive results from ULCA's Phase 1 dendritic cell vaccine trial in glioblastoma

A novel brain tumor vaccine clinical trial study demonstrates a longer survival time in patients with glioblastoma, according to findings being presented at the 79th Annual Scientific Meeting of the American Association of Neurological Surgeons in Denver.

12 Apr 2011

Positive results from laquinimod Phase III ALLEGRO study in multiple sclerosis to be presented at AAN

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today results from the two-year Phase III ALLEGRO study of laquinimod, an oral, once-daily, investigational immunomodulator for the treatment of relapsing forms of multiple sclerosis (MS). These data will be presented as late-breaking research at the Annual Meeting of the American Academy of Neurology (AAN).

12 Apr 2011

Novel drug holds potential against resistant chronic myeloid leukemia

A study from Tufts Medical Center researchers published today finds that a novel drug shows promise for treating leukemia patients who have few other options because their disease has developed resistance to standard treatment.

12 Apr 2011

Laquinimod drug greatly reduces number of relapses in patients with MS

The drug laquinimod reduced the number of relapses for people with multiple sclerosis, in a large, long-term Phase III clinical study that will be presented as late-breaking research at the 63rd Annual Meeting of the American Academy of Neurology, April 9-16, 2011, in Honolulu.

12 Apr 2011

Epilepsy medication USL255 associated with less fluctuation in plasma levels compared to topiramate IR

Upsher-Smith Laboratories today announced the presentation of data indicating that once daily administration of USL255, a proprietary extended-release (ER) formulation of the epilepsy medication topiramate, was associated with less fluctuation in topiramate plasma levels compared to immediate-release (IR) topiramate administered twice daily in healthy volunteers.

12 Apr 2011

NCI awards MabVax with Phase II SBIR grant to develop vaccine against recurrent sarcoma

MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has received the Phase 2 portion of the Small Business Innovation Research Grant from the National Cancer Institute under the agency's Streamlined Non-competing Award Procedures.

11 Apr 2011

Vanda initiates Fanapt Phase I study in patients with schizophrenia

Vanda Pharmaceuticals Inc. announced today that Novartis Pharmaceuticals Corporation, an affiliate of Vanda's sublicensor Novartis Pharma AG, has initiated a clinical study to evaluate the long-acting injectable formulation of Fanapt.

11 Apr 2011

Positive interim results from PROLOR's hGH-CTP Phase II trial in growth hormone deficiency

PROLOR Biotech, Inc. today reported positive interim efficacy results from a Phase II clinical trial of its long-acting CTP-modified version of human growth hormone in growth hormone deficient adults.

11 Apr 2011

Positive top-line results from Biogen BG-12 Phase 3 trial in RRMS

Biogen Idec announced today positive top-line results from DEFINE, the first of two pivotal Phase 3 clinical trials designed to evaluate the investigational oral compound BG-12 as a monotherapy in people with relapsing-remitting multiple sclerosis.

11 Apr 2011

The Lancet publishes VIVUS 56-week QNEXA study results in obesity

VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.

11 Apr 2011

Blood journal to publish Soliris study results in Paroxysmal Nocturnal Haemoglobinuria

The Canadian Association of PNH Patients welcomes the upcoming publication of a study that resoundingly proves the efficacy of Soliris, the first and only life-saving treatment for the ultra-rare blood disease known as Paroxysmal Nocturnal Haemoglobinuria.

11 Apr 2011

Synexus' Chief Medical Officer to discuss vaccine trial challenges at Washington event

Dr Glynis Neagle, Synexus' Chief Medical Officer will be discussing the challenges facing global vaccine trials at the World Vaccine Congress in Washington this week.

From AES - Accelerated Enrollment Solutions 11 Apr 2011

New experimental drug can help treat peripheral neuropathy in cancer patients

Although oncologists have made great strides in many aspects of cancer treatment, one area that has remained very difficult to treat is peripheral neuropathy, namely pain that can be caused by the cancer or by its treatment.

11 Apr 2011

Pfizer to support immatics' IMA901 Phase III trial in advanced renal cell carcinoma

immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that Pfizer has agreed to support its pivotal Phase III trial with IMA901, its therapeutic cancer vaccine for advanced renal cell carcinoma.

11 Apr 2011

Annals of Neurology publishes Diamyd Medical´s NP2 Enkephalin Phase I results in cancer pain

Diamyd Medical´s Phase I clinical trial results evaluating the safety and efficacy of the candidate drug NP2 Enkephalin to treat intractable cancer pain has been published in the medical journal Annals of Neurology.

11 Apr 2011

Drug Trial News

QRxPharma receives new U.S. Patent for MoxDuo IR in treatment of acute pain

Perampanel drug can effectively treat seizures in patients with epilepsy

Yissum announces successful Docetaxel pre-clinical data in cancer

Teva presents new CNS products study data in RRMS, Parkinson's at AAN meeting

Sirolimus may help treat lymphangioleiomyomatosis in women

Positive results from ULCA's Phase 1 dendritic cell vaccine trial in glioblastoma

Positive results from laquinimod Phase III ALLEGRO study in multiple sclerosis to be presented at AAN

Novel drug holds potential against resistant chronic myeloid leukemia

Laquinimod drug greatly reduces number of relapses in patients with MS

Epilepsy medication USL255 associated with less fluctuation in plasma levels compared to topiramate IR

NCI awards MabVax with Phase II SBIR grant to develop vaccine against recurrent sarcoma

Vanda initiates Fanapt Phase I study in patients with schizophrenia

Positive interim results from PROLOR's hGH-CTP Phase II trial in growth hormone deficiency

Positive top-line results from Biogen BG-12 Phase 3 trial in RRMS

The Lancet publishes VIVUS 56-week QNEXA study results in obesity

Blood journal to publish Soliris study results in Paroxysmal Nocturnal Haemoglobinuria

Synexus' Chief Medical Officer to discuss vaccine trial challenges at Washington event

New experimental drug can help treat peripheral neuropathy in cancer patients

Pfizer to support immatics' IMA901 Phase III trial in advanced renal cell carcinoma

Annals of Neurology publishes Diamyd Medical´s NP2 Enkephalin Phase I results in cancer pain

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

Latest News